GOOD10: The Pandemic Issue explores big-picture ways that science innovation and communication can usher in a more equitable, more progress-oriented, and safer world.
The GOOD10 format explores fundamental issues facing humanity through the lenses of ten forces pushing the needle toward progress: Places, Philanthropists, Celebrities, Whistleblowers, Companies, Media, Products, Politicians, Scientists, and Actions. Across these categories, we seek to present unexpected and encouraging paradigms emerging from this historic crisis.
TABLE OF CONTENTS:
55 Lessons Learned About Science Communication Around the World; Quarantining Our Way Into Outer Space
Quarantining Our Way Into Outer Space
An Exclusive Interview with Wendy Schmidt about Science in the Pandemic Era
Neil deGrasse Tyson Wants Celebrities to Promote Scientists
The Science Sleuths Holding Fraudulent Research Accountable
The Biggest Challenge for a COVID-19 Vaccine: Making It Accessible and Affordable
Isaac Asimov on the History of Infectious Disease—And How Humanity Learned To Fight Back
Will COVID-19 Pave the Way For DIY Precision Medicine?
Will the Pandemic Propel STEM Experts to Political Power?
Would a Broad-Spectrum Antiviral Drug Stop the Pandemic?
Pseudoscience is Rampant: How Not to Fall For It
How COVID-19 Could Usher In a New Age of Collective Drug Discovery
"The Pandemic Science Summit" focused on how science innovation is key to society's future stability as we emerge from the pandemic, featuring:
Christopher Bailey – Arts and Health Lead, World Health Organization
Elisabeth Bik, Ph.D. – Microbiologist and scientific integrity consultant
Margaret Hamburg, M.D. – Foreign Secretary, National Academy of Medicine; former Commissioner, U.S. Food and Drug Administration
Peggy Oti-Boateng, Ph.D. – Director, Division of Science Policy and Capacity- Building, UNESCO
George Yancopoulos, M.D., Ph.D. – President and Chief Scientific Officer, Regeneron Pharmaceuticals
COVID-19 vaccine development has advanced at a record-setting pace, thanks to our nation's longstanding support for basic vaccine science coupled with massive public and private sector investments.
Yet, policymakers aren't according anywhere near the same level of priority to investments in the social, behavioral, and data science needed to better understand who and what influences vaccination decision-making. "If we want to be sure vaccines become vaccinations, this is exactly the kind of work that's urgently needed," says Dr. Bruce Gellin, President of Global Immunization at the Sabin Vaccine Institute.
Simply put: it's possible vaccines will remain in refrigerators and not be delivered to the arms of rolled-up sleeves if we don't quickly ramp up vaccine confidence research and broadly disseminate the findings.